Premium
Urine of patients with early prostate cancer contains lower levels of light chain fragments of inter‐alpha‐trypsin inhibitor and saposin B but increased expression of an inter‐alpha‐trypsin inhibitor heavy chain 4 fragment
Author(s) -
Jayapalan Jaime J.,
Ng Keng L.,
Shuib Adawiyah S.,
Razack Azad H. A.,
Hashim Onn H.
Publication year - 2013
Publication title -
electrophoresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.666
H-Index - 158
eISSN - 1522-2683
pISSN - 0173-0835
DOI - 10.1002/elps.201200583
Subject(s) - alpha (finance) , trypsin inhibitor , trypsin , chemistry , urine , immunoglobulin light chain , prostate cancer , prostate , enzyme , microbiology and biotechnology , cancer , biochemistry , biology , medicine , immunology , antibody , construct validity , nursing , patient satisfaction
The present study was aimed at the identification of proteins that are differentially expressed in the urine of patients with prostate cancer ( PC a), those with benign prostatic hyperplasia ( BPH ) and age‐matched healthy male control subjects. Using a combination of 2 DE and MS / MS , significantly lower expression of urinary saposin B and two different fragments of inter‐alpha‐trypsin inhibitor light chain ( ITIL ) was demonstrated in the PC a patients compared to the controls. However, only one of the ITIL fragments was significantly different between the PC a and BPH patients. When image analysis was performed on urinary proteins that were transferred onto NC membranes and detected using a lectin that binds to O ‐glycans, a truncated fragment of inter‐alpha‐trypsin inhibitor heavy chain 4 was the sole protein found to be significantly enhanced in the PC a patients compared to the controls. Together, these urinary peptide fragments might be useful complementary biomarkers to indicate PC a as well as to distinguish it from BPH , although further epidemiological evidence on the specificity and sensitivity of the protein candidates is required.